Safety, tolerability and pharmacokinetic profile of recombinant human tissue kallikrein, DM199, after intravenous and subcutaneous administration in healthy volunteers

Michelle Alexander-Curtis, Jianmin Duan, Ashley Seeklander, Simon Scott, Nicola Norton, Chin Lin Wong, Sam Salman, Todd A. Verdoorn


Background: DM199 is a recombinant form of human tissue kallikrein (KLK1) that is being developed for ischemia-related diseases such as acute ischemic stroke. KLK1 is an important serine protease that promotes vasodilation and microcirculation in multiple tissues. Preclinical stroke studies demonstrate that KLK1 treatment promotes vasodilation, angiogenesis, prevents inflammation, and cerebral cell death.

Methods: The safety and tolerability, as well as the pharmacokinetic profile of DM199 was investigated in a Phase 1B clinical trial following an intravenously (IV) or subcutaneous (SC) administration.  Part A was a single ascending IV infusion of DM199 and Part B involved a single IV infusion and single SC dose in two different groups.

Results: For both routes of administration, DM199 was found to be safe and well tolerated at all doses given, albeit the PK profile differed between routes with respect to the time to maximum concentration and plasma half-life. Importantly, DM199 did not influence blood coagulation parameters, suggesting it could be safely used with other stroke treatments like tPA.  

Conclusions: Together, these results support the design of future studies to test the efficacy of DM199 in ischemic related diseases including in acute ischemic stroke (AIS).


Tissue kallikrein, Safety, Pharmacokinetic, Stroke

Full Text:



Golias C, Charalabopoulos A, Stagikas D, Charalabopoulos K, Batistatou A. The kinin system - bradykinin: biological effects and clinical implications. Multiple role of the kinin system - bradykinin. Hippokratia. 2007;11:124–8.

Raidoo D, Bhoola KD. Kinin receptors on human neurones. J Neuroimmunol. 1997;77:39–44.

Biyashev D. Kallikrein activates bradykinin B2 receptors in absence of kininogen. AJP Heart Circ. Physiol. 2005;290:1244–50.

Chao J, Buse J, Shimamoto K, Margolius HS. Kallikrein-induced uterine contraction independent of kinin formation. Proc Natl Acad Sci U.S.A. 1981;78:6154–7.

Hecquet C, Tan F, Marcic BM, Erdös EG. Human bradykinin B (2) receptor is activated by kallikrein and other serine proteases. Mol Pharmacol. 2000;58:828–36.

Regoli D, Gobeil F. Critical insights into the beneficial and protective actions of the kallikrein–kinin system. Vascul Pharmacol. 2015;64:1–10.

Moraes MS. Costa PE, Bastista WL, Pashcalin T, Curcio MF, Borges RE, et al. Endothelium-derived nitric oxide (NO) activates the NO-epidermal growth factor receptor-mediated signaling pathway in bradykinin-stimulated angiogenesis. Arch Biochem Biophys. 2014;558:14–27.

Su J, Tang Y, Zhou H, Liu L, Dong, Q. Tissue kallikrein protects neurons from hypoxia/reoxygenation-induced cell injury through Homer1b/c. Cell. Signal. 2012;24:2205–15.

Chen Z, Huang DQ, Niu FN, Zhang X, Li EG, Xu Y. Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-kappaB. J Cereb Blood Flow Metab. 2010;30:1356–65.

Nakayama Y, Furuta Y, Watanabe Y, Inoue T, Kurono M. Pharmacokinetic studies of human urinary kininogenase in healthy volunteers and animals. J Pharm Sci. 1996;85:1238–41.

Yang B, Shi J, Chen X, Ma B, Sun H. Efficacy and Safety of Therapies for Acute Ischemic Stroke in China: A Network Meta-Analysis of 13289 Patients from 145 Randomized Controlled Trials. PLOS ONE. 2014;9:e88440.

Zhang C, Tao W, Liu M, Wang D. Efficacy and safety of human urinary kallidinogenase injection for acute ischemic stroke: a systematic review. J Evid-Based Med. 2012;5:31–9.

Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA Reductase Inhibitor, Reduces Stroke Damage and Upregulates Endothelial Nitric Oxide Synthase in Mice. Stroke. 2001;32:980–6.

Emanueli C, Salis MB, Van Linthout S, Maloni M, Sesortes E, Silvestre JS, et al. Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation. 2004;110:1638–44.

Miura S, Matsuo Y, Saku K. Transactivation of KDR/Flk-1 by the B2 Receptor Induces Tube Formation in Human Coronary Endothelial Cells. Hypertension. 2003;41:1118–23.